Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden.
Metrics to compare | SPRINT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSPRINTPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.6x | −8.9x | −0.5x | |
PEG Ratio | 0.01 | −0.18 | 0.00 | |
Price/Book | 15.2x | 6.2x | 2.6x | |
Price / LTM Sales | 0.9x | 39.3x | 3.2x | |
Upside (Analyst Target) | 283.1% | 17.2% | 44.3% | |
Fair Value Upside | Unlock | 2.3% | 6.6% | Unlock |